Bone Marrow TransplantationTissue DonorsHistocompatibility TestingGraft vs Host DiseaseHistocompatibilityTransplantation, HomologousUnrelated DonorsGraft SurvivalBone MarrowAnemia, AplasticBone Marrow CellsLeukemiaTransplantation ChimeraTransplantation ConditioningSurvival AnalysisHematopoietic Stem Cell TransplantationRecurrenceWhole-Body IrradiationTreatment OutcomeTransplantation, AutologousHematologic NeoplasmsHLA AntigensGraft RejectionImmunosuppressive AgentsBusulfanCord Blood Stem Cell TransplantationLiving DonorsBone and BonesHematopoietic Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantation, IsogeneicLymphocyte DepletionBlood DonorsTransplantation ImmunologyKidney TransplantationRadiation ChimeraLiver TransplantationGraft Enhancement, ImmunologicTransplantation ToleranceActuarial AnalysisImmunosuppressionAcute DiseaseBone Marrow PurgingMice, Inbred C57BLDisease-Free SurvivalTime FactorsLeukemia, Myeloid, AcuteCyclophosphamideLeukocyte TransfusionChimerismBone Marrow DiseasesT-LymphocytesSkin TransplantationRemission InductionAntilymphocyte SerumHematopoiesisMyelodysplastic SyndromesRetrospective StudiesHematologic DiseasesPeripheral Blood Stem Cell TransplantationBone Marrow ExaminationStem Cell TransplantationCombined Modality TherapyHeart TransplantationSurvival RateBone Marrow NeoplasmsLeukemia, MyeloidCyclosporineHepatic Veno-Occlusive DiseaseLymphocyte TransfusionSevere Combined ImmunodeficiencyMyeloablative AgonistsVidarabineSiblingsDonor SelectionChimeraLymphocyte Culture Test, MixedLymphoma, Non-HodgkinFollow-Up StudiesMice, Inbred BALB CGraft vs Host ReactionGraft vs Tumor EffectColony-Forming Units AssayGraft vs Leukemia EffectFetal BloodCytomegalovirus InfectionsBone RemodelingHLA-DP beta-ChainsInfectionMelphalanNuclear FamilyHemibody IrradiationLife TablesMethotrexateGranulocyte Colony-Stimulating FactorLeukocyte CountAntineoplastic Combined Chemotherapy ProtocolsTissue and Organ ProcurementCytarabine